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Abstract
The title compound, which differs from the powerful O-GlcNAcase (OGA) inhibitor GlcNAc-
thiazoline only at the chalcogen atom (Se for S), is a much weaker inhibitor in a direct OGA 
assay. In human cells, however, the selenazoline shows comparable ability to induce hyper-O-
GlcNAc-ylation, and the two show similar reduction of insulin-stimulated translocation of glucose 
transporter 4 in differentiated 3T3 adipocytes.
Keywords
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1. Introduction
The dynamic post-translational modification of cytoplasmic and nuclear proteins by O-
linked 2-acetamido-2-deoxy-β-D-glucopyranosyl (O-GlcNAc) residues is an important 
signaling mechanism with analogies to phosphorylation.1 The diverse cellular functions that 
are affected include nutrient sensing,2 regulation of gene expression,3 target protein activity 
modification4 and protein degradation. 5 Disregulation of O-GlcNAc modification has been 
implicated in insulin resistance6 and Alzheimer’s disease.7 The recent discovery that 
transcription factor Forkhead Box Fox01 is regulated by this O-GlcNAc modification 
provides a potential mechanism by which hyperglycemia promotes gluconeogenesis and 
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worsening of glucose intolerance.8 O-GlcNAc metabolism is regulated by two key enzymes: 
O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA). OGT catalyzes the transfer of O-
GlcNAc from a UDP-GlcNAc donor to the various target proteins, and OGA catalyzes O-
GlcNAc hydrolytic removal.9 A number of mechanistic and inhibition studies10,11 have 
demonstrated that two aspartic acids (Asp174 and 175) in the OGA active site of the N-
terminal domain are key catalytic residues that enable a substrate-assisted mechanism. The 
inhibitor GlcNAc-thiazoline (1) and its relatives bind in enzyme active sites in the pseudo-
chair (4C1) conformation. Based on the correlation of free energy of activation calculated 
from enzymatic substrate hydrolysis relative to ΔG≠ for inhibitor binding, Vocadlo and co-
workers concluded that 1 and its analogues behave specifically as OGA transition state 
mimics.11 In this paper, we evaluate comparative OGA inhibition by the GlcNAc-
selenazoline (2), a close analogue of 1, but with greater lipophilicity and longer carbon–
chalcogen bonds.
OGA uses a double displacement mechanism (Fig. 1) that features substrate-assisted 
catalysis: the substrate A binds in the 1S3 twist boat conformation with co-linear orientation 
of the leaving aglycon oxygen and the approaching amide carbonyl oxygen. Bond rupture at 
the anomeric carbon (C-1) is accompanied by participation of the amide carbonyl from the 
opposite face. During the intramolecular “SN2-like” reaction, the pyranose ring flattens 
about C-1, and then inverts toward a bicyclic oxazolinium intermediate C through transition 
state B. On the basis of studies that include linear free energy correlations, X-ray 
crystallographic analyses, and computational modeling, Vocadlo and co-workers suggest 
that the thiazoline 1 in the chair conformation is closer to the trigonal bipyramidal “SN2” 
transition state B (Fig. 1) rather than the oxazolinium intermediate C.11 The highly 
structurally analogous α-Glc-NAc-selenazoline 2 might be anticipated to inhibit OGA 
analogously.
2. Results and discussion
2.1. Synthesis of GlcNAc-selenazoline
We have prepared 2 (Scheme 1) by treating β-D-glucosamine penta-acetate 4 with the 
Woollins reagent, [PhP(=Se)Se]2,12 followed by O-deacetylation. The purpose of the 
pyridine in the selenonation reaction is to neutralize the acid that accumulates during the 
cyclization. Without the added base, the acetic acid liberated by product formation is 
converted13 by the Woollins reagent to the (more acidic) selenoacetic acid, which causes 
counterproductive O-cyclization of 4 to an oxazoline.
2.2. OGA inhibition by GlcNAc-selenazoline
Evaluation of OGA inhibition by 2 was carried out by using FDGlcNAc (3)14 as the OGA 
substrate. A Lineweaver–Burk plot of the initial velocity at various concentrations of 2 
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shows that 2 competitively inhibits OGA with a Ki of 0.7 μM (Fig. 2). Compared with 1 (Ki 
= 0.01 μM), 2 is obviously a much less potent competitive inhibitor (about 70-fold; see Fig. 
3). For comparison, competitive inhibition Ki’s for 1 and 2 against a hexosaminidase from 
the bacterium Streptomyces plicatus (with p-nitrophenyl β-D-N-acetylglucosaminide as the 
substrate)15 are 20 and 170 μM, respectively, an eightfold difference. The disparity between 
1 and 2 as inhibitors might be attributable to, among other factors, the longer carbon–
chalcogen bond distance in 2, and the poorer ability of the divalent selenium atom (relative 
to sulfur) to act as a hydrogen bond acceptor in the active site. Among N-
acetylhexosaminidases, OGA is known to be relatively tolerant of small steric differences in 
the neighborhood of the substrate acetamido methyl group,11,16 but in this instance is 
responding dramatically to changes at the anomeric participating heteroatom.
The 4C1 chair conformation of 2 (shown) is calculated to be the most stable, according to ab 
initio calculations17 (B3LYP/6-31G*), which also estimate respective C–Se bond lengths of 
2.03 (to C-1) and 1.94 Å. Two other conformations, 0S2 and 1S3, are energetically accessible 
and may also contribute in solution. By comparison, small molecule crystallographic data 
for the 4C1 conformation of a 6-O-acylated derivative of 1 indicate respective C-S distances 
of 1.85 (to C-1) and 1.76 Å, and the corresponding calculated (B3LYP/6-31G*) distances 
are 1.89 and 1.80 Å, respectively.17 The respective carbon–chalcogen–carbon bond angles 
of 1 and 2 are calculated to be 87.8° and 83.2° (4C1 conformations), whereas the 
crystallographic C–S–C angle is 88.8°. The calculated 4C1 conformations of the GlcNAc-
oxazoline, -thiazoline (1), and - selenazoline (2) are displayed in Figure 4, overlapped at C-1 
and C-2 so as to emphasize the differences around the chalcogen and anomeric carbon.
A sequence aligning diagram (Section 3.6 and Fig. 8) allows comparison of the amino acid 
residues of human OGA, particularly those in the active site, with the corresponding 
residues of a bacterial OGA whose structure has been crystallographically determined.18
The selenium atom protrudes into the space occupied in OGA by Tyr219, a residue that is 
thought to act as a hydrogen bond donor to the substrate amide carbonyl oxygen, and 
thereby steer it into place beneath and close to C-1 (see threading diagram, Section 3.6). 
Furthermore, the selenium atom of 2 can be expected to accept a hydrogen bond from this 
residue much more weakly than O or S in the comparable position.19
2.3. Effect of 1 and 2 on global GlcNAc-ylation
In order to see whether 2 is able to induce hyper-O-GlcNAc-ylation in human cell lines, 
HT-29 and HeLa cells were incubated, respectively, in the absence and the presence of 
inhibitors (1 and 2) for 48 h. As shown in Figure 5, incubation of cells with 1 resulted in a 
significant increase in the globally O-GlcNAc-modified protein level, and the increase in the 
O-GlcNAc level by 2 was only marginally less than the O-GlcNAc level in the cells treated 
with 1. Internalization of 1 and 2 into the cells can be considered as a factor in this OGA 
inhibition experiment. Inhibitor 2 can be assumed to be somewhat more lipophilic than 1. 
For example, 2 has a higher chromatographic Rf than 1.20 The greater lipophilicity of 2 
relative to 1 (a much stronger inhibitor) may account for the fact that their cellular activities 
are similar.21
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2.4. Effect of 1 and 2 on the level of GLUT4 translocation
We have further examined the effect of 1 and 2, as well as PUGNAc (5), which has also 
been commonly used for the study of O-GlcNAcase inhibition,10,11 on the insulin-
stimulated translocation of glucose transporter 4 (GLUT4). GLUT4 is an isoform of glucose 
transporters that mediate glucose uptake in mammalian cells.22 It is selectively expressed in 
adipocytes and muscle,23 and continually recycles between the plasma membrane and 
intracellular storage sites.24 In the absence of insulin or other stimuli, approximately 90% of 
GLUT4 is localized in the intracellular storage sites.24 Upon insulin stimulation, net 
translocation of GLUT4 is induced from the intracellular storage sites to the plasma 
membrane and glucose uptake is stimulated.25 As described above, defects in O-GlcNAc 
cycling are known to be associated with diabetic insulin resistance. Elevated intracellular O-
GlcNAc modification of certain kinds of proteins involved in the insulin signaling pathway 
is suspected to suppress GLUT4 translocation, leading to insulin resistance.26 
Semiquantitative analysis of the translocation of GLUT4 in 3T3-L1 adipocytes can be 
performed by labeling GLUT4 on the plasma membrane with a cell-impermeant biotinylated 
bis(mannose) photolabeling agent, Bio-ATB-BMPA.27
We treated cells with the inhibitors 1, 2, and 5, measured GLUT4 on the plasma membrane 
by using the Bio-ATB-BMPA labeling agent, and compared the relative amounts of cell-
surface GLUT4 in the inhibitor-treated cells to that in untreated cells. Briefly, differentiated 
3T3 adipocytes cells incubated without and with each OGA inhibitor were stimulated with 
insulin, and then treated with Bio-ATB-BMPA. Following UV-irradiation-induced cross-
linking of the biotinylated photolabels to the adipocytes, cells were lysed and biotinylated. 
GLUT4 proteins on the cell surface were isolated using streptavidin beads from the same 
amounts of whole cell lysates. Then, isolated GLUT4 was analyzed by using conventional 
GLUT4 Western blots normalized to GAPDH (see Section 3.5 for the detailed experimental 
procedure). In each case, the levels of O-GlcNAc in the treated cells were monitored by 
RL-2 immunoblotting in parallel to confirm inhibition of O-GlcNAcase. As shown in Figure 
6, cells stimulated with insulin (1st lane) showed an increase in the amount of GLUT4 
translocated to the plasma membrane compared with unstimulated cells (2nd lane). 
However, treatment of cells with 1, 2 or 5 variably reduced the insulin-stimulated 
translocation of GLUT4 to the plasma membrane (43%, 16.3%, and 35.6%, respectively), 
indicating that each of these inhibitors has an effect on the glucose uptake in cells through 
the change in the level of GLUT4 exposed on the cell surface. The inhibitors also reduced 
the activation of PDK1 and AKT (data not shown). The inhibitors had no effect on total 
cellular GLUT4 levels (data not shown).
Recently, Vocadlo reported28 that an increase in the level of O-GlcNAc in 3T3-L1 
adipocytes treated with NButGT (1,2-dideoxy-2′-propyl-α-D-glucopyranoso-[2,1-D]-Δ2′-
thiazoline), a selective inhibitor for OGA but not the functionally similar lysosomal 
hexosaminidases (1:1200 selectivity), does not by itself cause insulin resistance. This is a 
surprising observation inasmuch as the growing body of evidence accumulated by studying 
inhibition by PUGNAc 5 (a non-selective inhibitor of both OGA and lysosomal 
hexosaminidases), as well as by genetic studies, suggests that elevated O-GlcNAc levels can 
either cause insulin resistance29 or result in perturbed glucohomeostasis.30 Like 5, 1 and 2 
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can inhibit lysosomal hexosaminidases A and B (Fig. 7). Therefore, the effect of those 
compounds on the reduction of insulin-stimulated GLUT4 translocation to the plasma 
membrane in 3T3-L1 adipocytes may not be caused by the inhibition of OGA and the 
increased O-GlcNAc levels. In order to clarify this further, and to get a better understanding 
of the effects of global increases of O-GlcNAc levels, future investigations should be 
performed using the array of selective OGA inhibitors now available.
3. Experimental
3.1. (3aR,5R,6S,7R,7aR)-5-(Hydroxymethyl)-2-methyl-5,6,7,7atetrahydro-3aH-pyrano[3,2-
d]selenazole-6,7-diol (2)
A mixture of 500 mg (1.30 mmol) of glucosamine penta-acetate 5, 1.00 g (1.90 mmol) of the 
Woollins reagent, 0.416 μL (5.12 mmol) of pyridine, and 6 mL of toluene was heated at 
reflux for 4 h. The resulting solution was allowed to cool to 23 °C, concentrated under 
reduced pressure, and then chromatographed on silica gel with 3:7 ethyl acetate/
dichloromethane as the eluant to give 414 mg (82%) of the GlcNAc-selenazoline triacetate 
as a colorless oil, Rf = 0.4, 2:3 ethyl acetate/dichloromethane: 1H NMR (400 MHz, CDCl3) 
δ 6.78 (d, 1H, J = 6.8 Hz), 5.60 (app t, 1H, J = 4.0, 3.2 Hz), 5.01 (dd, 1H, J = 9.6, 3.2 Hz), 
4.42–4.52 (m, 1H), 4.18 (dd, 1H, J = 12.4, 5.6 Hz), 4.14 (dd, 1H, J = 12.4, 3.2 Hz), 3.65 
(ddd, 1H, J = 9.6, 5.6, 3.2 Hz), 2.48 (d, 3H, J = 2.0 Hz), 2.15, 2.10, 2.09 (3s, 3H each); 13C 
NMR (100 MHz, CDCl3) δ 170.9, 169.9, 169.7, 169.7, 90.7, 76.8, 71.0, 70.4, 69.1, 63.1, 
24.7, 21.3, 21.2, 21.1; ESI-MS m/z 414 MNa+.
A solution of the GlcNAc-selenazoline triacetate (40 mg, 0.102 mmol) in 1 mL of methanol 
was treated at 0 °C with sodium methoxide (0.010 μL of a 1 M solution in methanol). After 
1 h at 0 °C, the solution was concentrated under vacuum and chromatographed on silica gel 
with 1:19 methanol/dichloromethane as the eluant to give 26 mg (95%) of triol 2 as a 
colorless oil, Rf 0.2, 1:19 methanol/dichloromethane: 1H NMR (500 MHz, CD3OD) δ 6.90 
(d, 1H, J = 6.0 Hz), 4.24 (ddd, 1H, J = 7.0, 6.5, 1.0 Hz), 3.87–3.91 (m, 3H), 3.77 (d, 1H, J = 
12.0, 6.5 Hz), 3.73 (d, 1H, J = 12.0, 4.5 Hz), 2.31 (d, 1H, J = 1.0 Hz); 13C NMR (125 MHz, 
CD3OD) δ 170.4, 93.6, 77.3, 75.9, 71.1, 67.5, 61.0, 24.6.; ESI-MS m/z 298 MNa+.
3.2. Determination of Ki’s for inhibition of OGA by 1 and 2
For inhibition studies of OGA by GlcNAc-thiazoline (1) and Glc-NAc-selenazoline (2), 
FDGlcNAc (3) was used as a fluorogenic substrate. The production of fluorescence was 
linear with time for the incubation period used, and less than 10% of the available substrate 
was hydrolyzed. Experiments were performed in duplicate. Human OGA was expressed and 
purified as previously described.14 Purified OGA was spin concentrated to 54 μg/mL, and 2 
μL of the enzyme solution was used. Determination of the inhibition constants of each 
inhibitor for OGA was performed assuming steady-state kinetics in the presence of different 
concentrations of the inhibitors (0, 0.005, 0.02, and 0.05 μM for 1; and 0.2, 0.4, 0.8, 1.2, 1.6, 
2.5, and 3.8 μM for 2 over a range of concentration (20–600 μM) of the substrate 3 in a final 
volume of 100 μL of the assay buffer (100 mM citrate/phosphate buffer, pH 6.5). The 
reaction was initiated by adding enzyme to the solution containing both 3 and the inhibitor at 
37 °C, and was stopped by adding 900 μL of aq Na2CO3 after a 5 min incubation period. 
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The mode of inhibition was visually verified by Lineweaver–Burk plot (see Fig. 2 in Section 
2.2 for 2; see Fig. 3 for 1), and the Ki was determined by fitting all initial reaction velocities 
to the standard equation for competitive type inhibition by using Enzyme Kinetics Pro 
software.
3.3. Analyses of inhibition of OGA and Hex A and Hex B by 1 and 2
An extract from Escherichia coli over-expressing OGA (2 μL; 0.02 nM) was added to a 
solution containing 50 μM of FDGlcNAc (Km = 85 μM) (3) as a substrate in the absence and 
the presence of 5 μM of the inhibitor (1 or 2) in 100 mM citrate/phosphate buffer, pH 6.5, 
containing 1 mM GalNAc in a final volume of 100 μL at the start of the incubation at 37 °C. 
The assay was terminated after 30 min incubation by adding 900 mL of a 0.5 M aq Na2CO3 
solution. The assay solution (200 μL) was transferred into a 96-well plate and fluorescence 
was measured at the excitation wavelength of 485 nm and at the emission wavelength of 535 
nm. Percent of inhibition was calculated by comparing enzyme activity in the absence of the 
inhibitor with the activity in the presence of the inhibitor. Human placental lysosomal 
hexosaminidase (Hex A, Sigma) assays were performed in the same manner as the O-
GlcNAcase assays described except that 1 mM of GalNAc was not present in the assays 
(Fig. 7, Section 2.4).
3.4. Analyses by western blot of the cellular O-GlcNAc levels in HT-29 and HeLa cells 
treated without and with the inhibitors 1 and 2
HeLa cells were seeded in a six well culture flask at a density of 1.0 × 105 cells in a 2 mL 
well and cultured in DMEM (Invitrogen) supplemented with 10% FBS (Invitrogen) in the 
absence and the presence of 40 μM of each inhibitor (1 or 2) at 37 °C for 2 days. Cultured 
cells were washed with PBS at pH 7.2, transferred to Eppendorf tubes, and then centrifuged 
at 2500g for 10 min. The pellets were lysed in 0.1 mL of MPER protein extraction reagent 
(Pierce) according to the manufacturer’s protocol. HT-29 cells were seeded in a six well 
culture flask at a density of 1.0 × 105 cells in a 2 mL well and cultured in McCoy’s 5a 
medium (ATCC) supplemented with 10% FBS (Invitrogen) in the absence and the presence 
of 40 μM of each inhibitor (1 or 2) at 37 °C for 2 days. Cultured HT-29 cells were washed 
with PBS at pH 7.2, transferred to Eppendorf tubes, and then centrifuged at 2500g for 10 
min. The pellets were suspended in 0.1 mL of lysis buffer containing 20 mM of Tris–HCl 
buffer, pH 8.0, 1 mM of DTT, 0.1% of Triton X-100, and EDTA-free protease inhibitor 
cocktail (1 tablet/10 mL). The suspension was incubated at room temperature for 5 min and 
then was sonicated on ice (4 × 10 s, setting 3, Misonix Ultrasonic Processor). The 
supernatant obtained after centrifugation at 20,000g for 15 min was stored at −20 °C. The 
Pierce BCA protein assay reagent was used to estimate protein concentration, with bovine 
serum albumin as the standard protein. Identical amounts of proteins (20 μg) were 
transferred to Eppendorf tubes in a volume of 22.5 μL, and then 7.5 μL of 4× NuPAGE® 
LDS sample buffer (Invitrogen) was added. The protein samples were heated at 80 °C for a 
10 min period, loaded onto a 10% NuPAGE pre-cast gel (Invitrogen), subjected to 
electrophoresis, and then transferred to a nitrocellulose membrane for Western blot analysis. 
The blot was probed with O-GlcNAc specific antibody RL2 (mouse IgG1, Affinity 
Bioreagents, Inc.) at 1:1000 dilution and with IR-dye (800 nm)-conjugated goat anti-mouse 
secondary antibody (Odyssey) at 1:10,000. The blot was imaged according to the 
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manufacturer’s instructions by using the Odyssey Infrared Imaging System (LICOR 
Biosciences, Lincoln, NE); see Figure 5, Section 2.3).
3.5. Labeling of cell surface GLUT4 in 3T3 adipocytes with biotin by using Bio-ATB-BMPA 
and semi-quantitative analysis of cell surface GLUT4
3T3-L1 fibroblasts were grown to confluency in a six well culture flask in DMEM–10% 
FBS, and were differentiated into adipocytes31 with minor modifications. Briefly, two days 
after confluency (day 0), cells were stimulated with an induction medium of DMEM–10% 
FBS containing 1 μM of dexamethasone (Sigma), 0.5 mM of isobutylmethylxanthine, and 
insulin (1 μg/mL, Sigma) for 2 days. Then (day 2), the induction medium was changed to an 
insulin medium for an additional two days. Two days later (day 4), the medium was changed 
to 10% FBS/DMEM. Cells were fed with 10% FBS/DMEM every 2 days. Adipocytes were 
used for experiments 8 days after addition of differentiation factors. 3T3-L1 adipocytes were 
cultured for 16 h in DMEM containing 4 mM glucose in the absence of serum and 
containing corresponding 40 μM of inhibitor [1, 2, or 5 (=PUGNAc)] or no inhibitor. After 
16 h, cells were re-fed in 10% FBS/DMEM solution; cells were then stimulated with insulin 
(30 nM) for 20 min except cells in one well that were not stimulated with insulin. The cells 
were washed with PBS, and then 400 μL of a 250 μM solution of 4,4′-O-[2-[2-[2-[2-[2-
(biotinylamino)ethoxy] ethoxy]ethoxy]-4-(1-azi-2,2,2,-trifluoroethyl)benzoyl]amino-1,3-
propanediyl]bis-D-mannose [Bio-ATB-BMPA, Toronto Research Chemicals, Inc.] in PBS 
were added to each well of the culture flask. Cells were irradiated for 30 s five times in a 
Rayonet photochemical reactor, using 300 nm lamps. Following irradiation, the cells were 
washed with ice-cold PBS three times, suspended in a homogenization PBS buffer 
containing 1% Triton X-100 and an EDTA-free protease inhibitor cocktail (1 tablet/10 mL), 
and then sonicated on ice (4 × 10 s, setting 3, Misonix Ultrasonic Processor). The 
supernatant was obtained after centrifugation at 20,000g for 30 min. The Pierce BCA protein 
assay reagent was used to estimate protein concentration by using bovine serum albumin as 
a standard protein. Identical amounts of proteins (600 μg) were transferred to Eppendorf 
tubes, and 40 μg of Streptavidin agarose beads was added to isolate biotin-tagged plasma 
membrane GLUT4. Sample mixtures were incubated with mixing at 4 °C overnight, and 
then were centrifuged at 3000g for 5 min. The supernatants were discarded and the beads 
were washed successively with PBS–0.1%SDS and with PBS. The washing buffer was 
removed, and 20 μL of SDS–PAGE (Invitrogen) sample buffer was added. The final resin 
samples were heated at 95 °C for 5 min, loaded onto a 10% NuPAGE pre-cast gel 
(Invitrogen), subjected to electrophoresis, and then transferred to a nitrocellulose membrane 
for Western blot analysis. The blot was probed with mouse anti-GLUT4 antibody (2 μg/mL, 
Sigma–Aldrich) and with IR-dye (800 nm)-conjugated goat anti-mouse secondary antibody 
(Odyssey) at 1:10,000. The blot was imaged by using the Odyssey Infrared Imaging System 
(LICOR Biosciences, Lincoln, NE) according to the manufacturer’s instruction (see Fig. 6, 
Section 2.4). In parallel, blots were probed with anti-GAPDH for normalization of integrated 
values.
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3.6. Threaded sequence and structural alignment of human O-GlcNAcase and bacterial 
OGA
Based on the report of van Aalten and co-workers (Ref. 18), the sequence of human O-
GlcNAcase (hOGA) was aligned with that of the family 84-fold member CpNAgJ from 
Clostridium perfrengens by using both the Align algorithm and adjustment of gap lengths by 
inspection (Fig. 8).
4. Conclusion
GlcNAc-selenazoline (2) is a close structural analogue of the potent OGA inhibitor GlcNAc-
thiazoline (1), differing only in the identity of the respective chalcogen (Se vs S). Despite 
this similarity, 2 is a weaker inhibitor, with Ki about 70-fold worse. This difference can be 
attributed to steric demands in the vicinity of the participating substrate carbonyl oxygen in 
the OGA active site (i.e., the Se containing inhibitor is a poorer fit). Alternatively, a key 
hydrogen bond between the Tyr219 hydroxyl and the inhibitor may be weaker where the Se 
atom of 2 is the H-bond acceptor, compared with the S atom of 1. Interestingly, studies on 
human cell lines indicate that 1 and 2 have similar effects on global Glc-NAc-ylation, a 
result that can be rationalized by postulating that 2 (the weaker OGA inhibitor) is 
internalized into cells more easily than 1.
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Abbreviations
O-GlcNAcase β-N-acetylglucosaminidase
UDP-GlcNAc uridine diphosphate N-acetylglucosamine
Bio-ATB-BMPA 4,4′-O-[2-[2-[2-[2-[2-(biotinylamino)ethoxy]ethoxy]ethoxy]-4-(1-
azi-2,2,2,-trifluoroethyl)benzoyl]amino-1,3-propanediyl]bis-D-
mannose
DMEM Dulbecco’s modified Eagle’s medium
PBS phosphate buffered saline
FBS fetal bovine serum
PUGNAc O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-
phenylcarbamate
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Figure 1. 
Substrate-assisted catalytic hydrolysis mechanism used by OGA (A → [B]‡ → C → D).
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Figure 2. 
Lineweaver–Burk analysis of OGA inhibition in the absence and the presence of increasing 
concentrations of 2 with FDGlcNAc 3 as substrate.
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Figure 3. 
Lineweaver–Burk analysis of OGA inhibition in the absence and the presence of increasing 
concentrations of 1 with FDGlcNAc 3 as substrate.
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Figure 4. 
Calculated 4C1 structures of oxazoline intermediate C, thiazoline 1, and selenazoline 2 
overlapped at C-1 and C-2 (carbohydrate numbering), showing the respective chalcogens 
protruding at center bottom. Atom colors: red (oxygen), blue (nitrogen), yellow (sulfur), and 
orange (selenium).
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Figure 5. 
An increase in O-GlcNAc level by the treatment of cells with inhibitors 1 and 2. HT-29 (A) 
and HeLa (B) cells were incubated in the absence and the presence of the inhibitor for 48 h.
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Figure 6. 
Treatment of cells with OGA inhibitors (1, 2, or 5) results in a reduction of insulin-
stimulated GLUT4 translocation.
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Figure 7. 
Analysis of inhibition of OGA and Hex A and B by GlcNAc-thiazoline (1) and GlcNAc-
selenazoline (2).
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Figure 8. 
(A) Sequence alignment of hOGA with CpNAgJ. Areas of high sequence similarity are 
shaded gray. Catalytically important residues such as Tyr335 (corresponding to hOGA 
Tyr219) are highlighted in yellow. (B) The crystal structure of CpNAgJ, with the 
catalytically important Tyr335 and the site of the predicted Cys215 in hOGA (here, Val331) 
highlighted in yellow. PugNAc (5) is shown bound to the active site of CpNAgJ in this 
structure.
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Scheme 1. 
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